Macrophages do not occupy one permanent activation state. They integrate cytokines, metabolites, lipids, immune complexes, microbial products, dying cells, matrix signals, oxygen tension, and tissue-specific instructions, then adjust their transcriptional, metabolic, and functional programs. The familiar M1 and M2 terms remain useful as experimental reference points, but they describe ends of a broad response landscape rather than two mutually exclusive cell identities. In tissues and disease models, macrophages commonly display mixed, transitional, or stimulus-specific features that cannot be captured by a single marker.

Creative Biolabs provides a practical map of major macrophage phenotypes. For programs that require model development, Creative Biolabs can align cell source, stimulation conditions, marker panels, and functional endpoints through a customized macrophage polarization assay. The same framework can support exploratory profiling, candidate screening, mechanism-of-action studies, and translational biomarker development.

Understanding Macrophage Phenotype as a Dynamic Spectrum

A macrophage phenotype is best defined as a measured state under specified conditions. The label should be accompanied by the cell source, species, tissue, differentiation protocol, stimulus identity and concentration, exposure time, washout or recovery period, and assay readouts. A monocyte-derived macrophage treated with lipopolysaccharide and interferon-gamma for 24 hours is not interchangeable with a tissue-resident macrophage isolated from an inflamed organ, even when both express inflammatory genes. Likewise, two cells that share CD206 expression can differ in cytokine release, efferocytosis, metabolic pathway use, and their effect on neighboring cells.

Consensus nomenclature encourages researchers to report the activating stimulus instead of relying only on M1 or M2 shorthand. This approach improves reproducibility because macrophage programs can change with dose, duration, substrate, serum, oxygen, and culture density. It also acknowledges that human and mouse macrophages do not use every marker in the same way. For example, inducible nitric oxide synthase and arginase-1 are widely used in mouse systems, but their interpretation in human macrophages requires caution and should be supported by species-appropriate readouts.

Modern single-cell and spatial methods reinforce this continuum model. They reveal macrophage clusters associated with interferon signaling, lipid handling, phagocytosis, matrix remodeling, stress responses, proliferation, antigen presentation, or monocyte recruitment. Cluster names are convenient summaries, not proof of a fixed lineage or function. Functional validation and careful comparison with reference signatures are necessary before a newly observed cluster is equated with an established phenotype.

Phenotype Atlas

M1 Macrophage Phenotype

M1 is a conventional term for a classically activated, inflammation-associated macrophage program. In vitro models commonly use interferon-gamma together with a microbial signal such as lipopolysaccharide or another Toll-like receptor agonist. The resulting cells can increase antigen-processing and antigen-presentation machinery, inflammatory cytokines, chemokines, antimicrobial pathways, and reactive oxygen or nitrogen species. These responses can strengthen early defense against intracellular pathogens and support type 1 immune responses, but persistent or poorly controlled activation may also amplify tissue injury.

• Representative signals - IFN-gamma, LPS or other TLR ligands, TNF, and selected pathogen-associated molecular patterns. The exact combination matters: IFN-gamma alone, LPS alone, and IFN-gamma plus LPS are related but non-identical conditions.
• Candidate readouts - TNF, IL1B, IL6, IL12 family members, CXCL9, CXCL10, HLA-DR or MHC-II, CD80, CD86, interferon-response genes, NF-kappaB activation, antimicrobial activity, glycolytic remodeling, and species-appropriate nitric oxide measurements. None should be used as a universal stand-alone marker.
• Functional interpretation - A robust M1-like claim should connect the molecular profile to function, such as inflammatory mediator release, enhanced antigen presentation, pathogen restriction, tumor-cell interaction, or a measurable effect on T-cell activation. Cytokine production alone may reflect acute stimulation without establishing a stable phenotype.

M2 Macrophage Phenotype

M2 is an umbrella term for alternatively activated or resolution- and repair-associated macrophage programs. The best-characterized experimental model uses IL-4 and/or IL-13, but literature also describes immune-complex-, IL-10-, glucocorticoid-, and tumor-associated programs under the M2 label. These stimuli do not create one uniform state. They can produce distinct transcriptional profiles and functions involving tissue repair, extracellular matrix remodeling, scavenging, efferocytosis, immune regulation, parasite defense, angiogenesis, or fibrosis.

• Representative signals - IL-4 and IL-13 for an M2a-like program; immune complexes combined with innate stimuli for M2b-like responses; IL-10, TGF-beta, or glucocorticoids for M2c-like regulatory features; and tumor-derived or adenosine-rich cues for states sometimes called M2d. These sublabels should always be paired with the actual induction protocol.
• Candidate readouts - CD206/MRC1, CD163, CCL17, CCL18, CCL22, IL10, scavenger receptors, efferocytosis, matrix-related mediators, and oxidative metabolic features. Marker relevance varies by species, tissue, and stimulus. ARG1, for example, is informative in many murine models but is not a universal marker of human alternative activation.
• Functional interpretation - Evidence may include apoptotic-cell clearance, suppression or redirection of inflammatory responses, fibroblast crosstalk, collagen-related signaling, wound-closure support, angiogenic activity, or altered T-cell polarization. Repair-associated activity is not automatically beneficial; sustained remodeling signals may contribute to fibrosis, immune exclusion, or tumor progression.

Mox Macrophage Phenotype

Mox describes a macrophage state induced by oxidized phospholipids and characterized by a prominent oxidative-stress response. It was identified in atherosclerosis-focused research and is associated with activation of the transcription factor NRF2 and expression of antioxidant and detoxification genes. Mox-like cells can differ from conventional M1- and M2-polarized macrophages in surface markers, redox handling, phagocytic performance, and inflammatory outputs. The phenotype is therefore especially relevant when a model includes oxidized lipids, lipid peroxidation products, vascular injury, or chronic oxidative stress.

• Representative signals - Oxidized phospholipids, including oxidized phosphatidylcholine species, and other redox-active conditions capable of engaging NRF2-linked stress responses. Reagent composition and oxidation state should be documented because heterogeneous lipid preparations may produce variable results.
• Candidate readouts - HMOX1, NQO1, TXNRD1, GCLM, SRXN1, and other NRF2-regulated antioxidant or phase II detoxification genes, together with lipid uptake, oxidative-stress measurements, viability, inflammatory mediator profiling, and phagocytic function. The signature should be compared with unstimulated and relevant oxidized-lipid controls.

Mhem Macrophage Phenotype

Mhem refers to a heme-exposed, hemorrhage-associated macrophage program described in regions of intraplaque bleeding. These macrophages encounter hemoglobin, heme, erythrocyte material, and oxidative stress. They can increase heme-processing and antioxidant pathways, including heme oxygenase-1, and show features linked to iron handling, cholesterol export, and protection from lipid accumulation. Mhem biology is relevant to atherosclerotic plaque progression, erythrophagocytosis, hematoma resolution, hemolytic conditions, and other settings where macrophages process red-cell-derived material.

• Representative signals - Hemoglobin-haptoglobin complexes, heme, oxidized erythrocytes, or controlled erythrophagocytosis models. CD163-mediated hemoglobin scavenging and pathways involving HMOX1, ATF1, and liver X receptor signaling have been associated with this state, but experimental context and species remain important.
• Candidate readouts - CD163, HMOX1, ferritin and iron-handling proteins, cholesterol efflux transporters such as ABCA1 and ABCG1, oxidative-stress resistance, heme degradation, iron storage, lipid accumulation, and cytokine profiles. The relationship between CD163 and function should be tested rather than inferred from expression alone.

M4 Macrophage Phenotype

M4 macrophages are an experimentally defined phenotype induced by the platelet chemokine CXCL4, also known as platelet factor 4. This state was developed in the context of vascular inflammation and atherosclerosis. CXCL4-conditioned macrophages show a transcriptional program distinct from conventional M1 and M2 references, with reported changes in scavenger receptors, inflammatory mediators, matrix-degrading enzymes, and iron-handling pathways. Reduced CD163 expression is a frequently cited feature, which contrasts with the CD163-high heme-handling program associated with Mhem macrophages.

• Representative signals - CXCL4 exposure during macrophage differentiation or activation. Protocol details are critical because CXCL4 concentration, treatment duration, monocyte source, serum conditions, and the presence of additional cytokines can alter the observed state.
• Candidate readouts - CXCL4-responsive transcriptional changes, reduced CD163, selected matrix metalloproteinases, inflammatory chemokines, scavenger-receptor patterns, phagocytosis, foam-cell formation, and matrix-remodeling activity. There is no single universally accepted M4 marker panel, so reference-condition comparisons and multiple assay layers are essential.

Other Types and Sub-types of Macrophage

Many biologically important macrophage states are better defined by tissue origin, ontogeny, disease environment, or a specific function than by the M1/M2/Mox/Mhem/M4 vocabulary.

• Tissue-resident macrophages - Microglia in the central nervous system, Kupffer cells in the liver, alveolar macrophages in the lung, osteoclast-lineage cells in bone, intestinal macrophages, splenic macrophages, and cardiac macrophages receive local developmental and metabolic instructions. Their baseline identity may be more informative than an activation label. Tissue-specific transcription factors, niche factors, self-renewal capacity, and developmental origin should be considered when translating data from monocyte-derived cultures.
• Monocyte-derived and recruited macrophages - During inflammation, circulating monocytes enter tissues and differentiate under local signals. These cells can overlap phenotypically with resident macrophages while retaining recruitment- or inflammation-associated features. Lineage tracing in animals, donor-aware single-cell analysis, and combinations of surface, transcriptional, and spatial evidence can help distinguish origin and state.
• Tumor-associated macrophages - TAMs are shaped by tumor cells, hypoxia, metabolites, stromal cells, therapy, and immune checkpoints. Some TAMs suppress T-cell activity or promote angiogenesis and matrix remodeling; others can present antigen, phagocytose tumor cells, or support inflammatory antitumor responses. The M2 label is insufficient for this diversity. Therapeutic studies may evaluate depletion, recruitment blockade, repolarization, checkpoint modulation, or enhancement of phagocytosis.
• Disease-associated and lipid-associated macrophages - TREM2-, APOE-, LPL-, SPP1-, or lipid-metabolism-associated signatures occur in several metabolic, fibrotic, neurodegenerative, and tumor settings. Similar gene modules can appear across tissues, but their functions are not necessarily identical. Investigators should combine lipid handling, efferocytosis, localization, matrix interaction, and disease-stage information with transcriptomic signatures.
• Regulatory macrophages - Macrophages generated under combinations of immune complexes, anti-inflammatory cytokines, glucocorticoids, prostaglandins, adenosine, or other signals may restrain inflammation and alter adaptive immunity. The term regulatory macrophage, or Mreg in some protocols, should be tied to a defined induction method and functional evidence such as suppression of responder-cell activation or characteristic cytokine production.
• Repair-, fibrosis-, and scar-associated macrophages - Macrophages can coordinate debris clearance, fibroblast activation, vascular remodeling, and extracellular matrix turnover. Repair is time-dependent: early inflammation may be required for pathogen control or debris removal, whereas persistent profibrotic signaling can become pathological. Spatial position and disease stage are therefore central to interpretation.
• Infection-associated programs - Bacteria, viruses, fungi, parasites, and their products activate different receptor combinations and metabolic pathways. A macrophage can display interferon-stimulated genes, inflammasome activation, antimicrobial functions, or immune-evasion responses without matching a textbook M1 state. Pathogen burden, intracellular killing, cell death, and downstream lymphocyte effects provide essential functional context.
• Specialized experimental subtypes - Researchers may define states by IL-10, immune complexes, apoptotic cells, glucocorticoids, hypoxia, lactate, adenosine, fatty acids, nanoparticles, biomaterials, mechanical cues, or engineered gene perturbations. These models are valuable when the nomenclature remains transparent: stimulus, dose, duration, source, and readout should travel with the label.

Projects centered on resident-cell identity can be connected to tissue-specific macrophage development services, while studies beginning with primary cells or monocytes can use a customized macrophage isolation and culture workflow.

At-a-Glance Comparison of Major Phenotypes

Designing a Reliable Macrophage Phenotyping Study

A robust phenotyping plan begins with the biological decision the data must support. Discovery studies may require broad single-cell, transcriptomic, proteomic, metabolic, or secretome profiling. Screening studies need scalable endpoints with strong assay windows. Mechanism studies require perturbations, temporal sampling, and pathway validation. Translational studies must account for donor variation, tissue processing, clinical covariates, and the feasibility of measuring the proposed biomarker in the intended sample type.

1. Choose the Cell Source and Reference Conditions

Primary tissue macrophages offer biological relevance but may be scarce, heterogeneous, and sensitive to isolation. Blood monocyte-derived macrophages are accessible and configurable, yet they do not fully reproduce tissue-resident identity. Bone-marrow-derived macrophages are useful in murine work but depend on differentiation factors and mouse strain. Cell lines provide throughput but may diverge from primary cells. iPSC-derived and engineered systems can improve consistency or enable genetic studies, although their maturation state must be characterized.

Every study should include an appropriate unstimulated or baseline macrophage condition and, when possible, stimulus-specific positive controls. Comparing a candidate only with nominal M1 and M2 endpoints can hide a more relevant effect, such as oxidative-stress adaptation, impaired efferocytosis, altered lipid handling, or a tissue-specific state transition.

2. Build a Multi-Layer Marker Strategy

No phenotype is established by one surface protein. A defensible panel combines identity markers, stimulus-responsive markers, intracellular pathways, secreted mediators, and functional outputs. Flow cytometry and imaging can quantify protein expression and heterogeneity. Targeted qPCR or transcriptomics can capture pathway programs. Multiplex cytokine assays reveal secreted activity. Metabolite measurements and extracellular flux assays can add functional context. The selected layers should address the study question without creating a panel so broad that interpretation becomes unfocused.

Creative Biolabs can support species- and context-aware panel selection through macrophage marker development and can pair intracellular or surface phenotyping with cytokine expression profiling.

3. Connect Phenotype to Function

Functional assays test whether a molecular change matters. Depending on the model, these may include phagocytosis, efferocytosis, intracellular killing, reactive species generation, antigen presentation, T-cell activation, lipid uptake and efflux, heme processing, matrix degradation, fibroblast activation, endothelial interaction, tumor-cell phagocytosis, or response to therapeutic modulation. Functional effects should be normalized for cell number and viability so that reduced activity is not mistaken for successful repolarization when it actually reflects cytotoxicity.

Common downstream routes include phagocytosis capacity analysis and antigen-presenting capacity assessment. Each link is most useful when the surrounding study already defines the phenotype, target function, and comparison condition.

4. Control Time, Dose, and Plasticity

Macrophage states can emerge rapidly and then resolve, persist, or transition after the stimulus is removed. A single endpoint may miss an early inflammatory burst, delayed repair program, tolerance response, or recovery phase. Time-course designs are particularly useful for sequential stimuli, repolarization studies, and models of disease progression. Dose-response testing can identify thresholds and distinguish pathway-specific effects from stress or toxicity. Washout and restimulation experiments help determine whether a change is transient, refractory, or stably maintained under the tested conditions.

5. Plan Analysis Before Data Collection

The analysis plan should define biological replicates, technical replicates, donor handling, exclusion criteria, normalization, batch controls, and the primary endpoint. For high-dimensional data, clustering and dimensionality reduction are exploratory tools; they should be paired with differential expression, pathway analysis, orthogonal protein measurements, and functional validation. Predefined reference signatures can be useful, but scoring methods should not force mixed states into binary classes. Reporting effect sizes and uncertainty is more informative than listing statistically significant markers without biological context.

Integrated Macrophage Phenotype Service Platform

Creative Biolabs provides customized macrophage study support for researchers who need to generate, characterize, compare, or modulate macrophage phenotypes. Projects can be assembled from modular capabilities and adapted to the target species, tissue, indication, therapeutic modality, and development stage. The page should position the service platform as a route from a defined biological question to an interpretable experimental package, not as a promise that every phenotype can be represented by the same standard protocol.

• Primary macrophage, monocyte-derived macrophage, cell-line, animal-derived, iPSC-derived, or engineered macrophage model selection
• Baseline differentiation and phenotype induction using cytokines, innate ligands, lipids, heme-related stimuli, CXCL4, metabolites, disease-associated factors, or client-defined conditions
• Flow cytometry, imaging, gene-expression, secretome, protein, metabolic, and pathway-focused characterization
• M1-, M2-, Mox-, Mhem-, M4-, tissue-associated, tumor-associated, inflammatory, regulatory, or custom-state comparison
• Phagocytosis, efferocytosis, antigen presentation, cytokine release, oxidative stress, lipid handling, matrix interaction, and co-culture assays
• Candidate drug, biologic, nanoparticle, gene-modulation, or delivery-system screening
• Mechanism-of-action, target validation, biomarker discovery, and treatment-response studies
• Pilot studies designed to establish assay feasibility, dynamic range, and decision criteria before larger programs

For projects involving delivery technologies, phenotype measurement can be combined with uptake, trafficking, viability, inflammatory-response, and functional assays. This is particularly important because efficient macrophage uptake may be beneficial for targeted immunomodulation but problematic for formulations intended to avoid rapid clearance. A customized macrophage-targeted delivery program can therefore evaluate both disposition and biological consequence.

Explore macrophage-targeted drug delivery system development for delivery-focused workflows, or use the inquiry section to discuss a phenotype-centered assay package.

Related Products

Q & A

Q: Are M1 and M2 macrophages two fixed cell types?

A: No. M1 and M2 are useful reference programs, but macrophages in tissues usually occupy a continuum of mixed and changing states. A phenotype should be reported with its cell source, stimulus, timing, markers, and functional readouts.

Q: Which markers should be used to identify a macrophage phenotype?

A: Use a panel rather than one marker. Combine macrophage identity, stimulus-responsive surface or intracellular markers, secreted mediators, pathway activity, and a function relevant to the study. Marker selection must be species- and context-aware.

Q: How are Mox and Mhem macrophages different?

A: Mox is primarily associated with oxidized phospholipid exposure and an NRF2-linked antioxidant program. Mhem is associated with hemoglobin or heme handling in hemorrhagic environments and may show HMOX1, CD163, iron-handling, and cholesterol-efflux features. They can share stress-response elements but arise from different experimental cues.

Q: What defines an M4 macrophage?

A: M4 is an experimental macrophage state induced by CXCL4, or platelet factor 4, in vascular-inflammation research. Reported features include a distinct transcriptional program and reduced CD163, but no single marker is sufficient and the nomenclature is less standardized than broad M1/M2 reference activation.

Q: Can Creative Biolabs develop a custom macrophage phenotype model?

A: Yes. A project can be designed around the required cell source, species, tissue context, stimulus, disease environment, therapeutic modality, marker panel, and functional endpoint. A pilot phase is often useful when the state is complex or the assay window has not been established.

Q: How should single-cell macrophage clusters be named?

A: Name clusters conservatively using dominant programs, tissue context, or validated markers. Avoid equating a cluster automatically with M1 or M2. Confirm the signature with orthogonal measurements and, when possible, a relevant functional assay.

Start a Macrophage Phenotype Project

Macrophage plasticity creates experimental complexity, but it also creates opportunities to discover actionable pathways, biomarkers, and therapeutic responses. A successful study does more than assign a label: it defines the conditions that produced the state, measures the pathways that sustain it, and demonstrates a function connected to disease or treatment.

Creative Biolabs can help translate a macrophage phenotype question into a staged experimental plan, from cell sourcing and model establishment through multi-layer characterization and functional validation. Contact us with your target phenotype, cell source, indication, candidate type, preferred readouts, and development objective to begin a customized project discussion.